Connor Iapoce

The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations in ophthalmology research.

People experiencing homelessness exhibit similar rates of morbidity compared with housed patients, but a longer adjusted length of hospital stay.

Brassica Pharma Pvt. Ltd. is voluntarily recalling eye ointment products with expiration dates from February 2024 to September 2025.

Introduction of curated materials to assist clinicians was linked to better rates of screening and treatment of iron deficiency anemia among patients with heart failure.

An ancillary study of the phase 2 HOPE-KIDS 1 trial revealed voxelotor is associated with reduced sickling and hemolysis in children with SCD.

More than half of older patients admitted to geriatric units in France had iron deficiency, including patients without anemia.

A large language model demonstrated comparative diagnostic accuracy and completeness in glaucoma and retina disease to fellowship-trained ophthalmologists.

Worse examination-based and self-reported vision impairment was associated with depressive and anxiety symptoms among adults aged ≥65 years.

Rusfertide maintained a hematocrit of <45% and reduced or eliminated the use of phlebotomy in patients with polycythemia vera.

A meta-analysis revealed a higher prevalence of abnormal ECG findings in individuals with SCD compared to those without the disease.

A meta-analysis of four RCTs found Iron isomaltoside ferumoxytol is both effective and safe to treat iron deficiency anemia.

Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.

No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.

A recent case series analysis found the fungal keratitis prevalence may be twice as high in rural compared with non-rural areas in the United States.

Hearing loss was more prevalent among children and adults with sickle cell disease and its traits compared to matched controls with normal hemoglobin.

Over the study period, pain screening procedures were integrated within routine clinical visits and providers’ workflow in sickle cell disease care.

Microalbuminuria and low body iron levels displayed a significant association with pediatric hearing loss independently.

The approval provides patients with the first-ever treatment option for severe frostbite to prevent the amputation of fingers or toes.

In a phase 3 trial in China, QL1207 demonstrated equivalent efficacy to aflibercept with a similar safety profile for patients with nAMD.

Mitapivat treatment was linked to long-term improvements in key markers of iron homeostasis and erythropoiesis in an analysis of the phase 3 ACTIVATE trial.

Non-breast milk-fed infants received more iron on average each day than breast-milk-fed infants, but experienced a higher rate of iron deficiency.

A new analysis cites relatively high hemoglobin levels as a protective factor for bone quality in patients with type 2 diabetes.

In a new episode of New Insight with Veeral Sheth, MD, a trio of retina specialists host a well-rounded conversation on recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.

Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.

A new proof-of-concept observation study reports the dual GLP-1/GIP agonist's positive efficacy and safety for adults with T1D.

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

Since the Baby Boomers are transitioning into older age by 2040 and 2050, the dramatic rise in the global aging population will increase demands for ophthalmic care.

SARS-CoV-2 antibody levels did not change significantly in patients receiving originator adalimumab, while patients receiving the biosimilar experienced a significant decrease.

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.